These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16706678)

  • 1. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
    Gould TD
    Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
    Gould TD; Picchini AM; Einat H; Manji HK
    Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
    Cole AR
    FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
    Costemale-Lacoste JF; Guilloux JP; Gaillard R
    Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.
    Li X; Bijur GN; Jope RS
    Bipolar Disord; 2002 Apr; 4(2):137-44. PubMed ID: 12071511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
    Munch G; Godart N
    Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
    Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
    J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice.
    Pan JQ; Lewis MC; Ketterman JK; Clore EL; Riley M; Richards KR; Berry-Scott E; Liu X; Wagner FF; Holson EB; Neve RL; Biechele TL; Moon RT; Scolnick EM; Petryshen TL; Haggarty SJ
    Neuropsychopharmacology; 2011 Jun; 36(7):1397-411. PubMed ID: 21389981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
    Gould TD; Zarate CA; Manji HK
    J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors.
    Gould TD; Einat H; O'Donnell KC; Picchini AM; Schloesser RJ; Manji HK
    Neuropsychopharmacology; 2007 Oct; 32(10):2173-83. PubMed ID: 17299510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
    Amar S; Belmaker RH; Agam G
    Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is glycogen synthase kinase-3 a central modulator in mood regulation?
    Li X; Jope RS
    Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].
    Ivanova SA; Losenkov IS; Bokhan NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):93-100. PubMed ID: 25075421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
    Wada A
    J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Wnt signaling pathway in bipolar disorder.
    Gould TD; Manji HK
    Neuroscientist; 2002 Oct; 8(5):497-511. PubMed ID: 12374432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
    Manduca JD; Thériault RK; Perreault ML
    Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
    Pandey GN; Ren X; Rizavi HS; Dwivedi Y
    J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.